The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the treatment of adults with KRAS-mutated, recurrent low-grade serous ovarian ...
Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets. PROTA: A phase I ...
Verastem Oncology Inc. CEO Dan Paterson said he is “not expecting a huge bolus [of ovarian cancer patients] at the beginning” of Avmapki/Fakzynja’s launch, but momentum will build over time. “Based on ...
Cancer that develops in the ovaries (the egg-producing reproductive organs) is referred to as ovarian cancer. There are three types of ovarian cancer. Each type has differences in how they will ...
Leveraging genomic instability scores (GIS) to investigate BRCA variants of unknown significance (VUS) in ovarian cancer: An analysis of 14,513 patients in the Myriad Collaborative Research Registry ...
Avmapki Fakzynja is a type of targeted medicine called a tyrosine kinase inhibitor (TKI). TKIs are used to treat many different types of cancers, including ovarian cancer. Avmapki Fakzynja is ...
Verastem Oncology Inc. CEO Dan Paterson said he is “not expecting a huge bolus [of ovarian cancer patients] at the beginning” of Avmapki/Fakzynja’s launch, but momentum will build over time. “Based on ...
Editor’s Note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Increasing understanding of the molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results